IDD Stock Overview
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IDD from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.90 |
| 52 Week High | €2.73 |
| 52 Week Low | €1.34 |
| Beta | 0.94 |
| 1 Month Change | 10.31% |
| 3 Month Change | -10.40% |
| 1 Year Change | -25.91% |
| 3 Year Change | -30.91% |
| 5 Year Change | -65.88% |
| Change since IPO | -59.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.0% | -0.5% | 1.1% |
| 1Y | -25.9% | -13.0% | 16.0% |
Return vs Industry: IDD underperformed the German Biotechs industry which returned -13.5% over the past year.
Return vs Market: IDD underperformed the German Market which returned 15% over the past year.
Price Volatility
| IDD volatility | |
|---|---|
| IDD Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: IDD has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: IDD's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 181 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
| IDD fundamental statistics | |
|---|---|
| Market cap | €180.63m |
| Earnings (TTM) | -€49.47m |
| Revenue (TTM) | €20.12m |
Is IDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDD income statement (TTM) | |
|---|---|
| Revenue | €20.12m |
| Cost of Revenue | €51.98m |
| Gross Profit | -€31.86m |
| Other Expenses | €17.61m |
| Earnings | -€49.47m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 17, 2025
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -158.34% |
| Net Profit Margin | -245.87% |
| Debt/Equity Ratio | 346.6% |
How did IDD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 15:45 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olga Smolentseva | Bryan Garnier & Co |
| Yigal Nochomovitz | Citigroup Inc |
| Michael Thomas Cooper | Edison Investment Research |